Latest News

Health Canada Authorizes Lebrikizumab for Moderate to Severe Atopic Dermatitis in Patients 12 Years and Older
Health Canada Authorizes Lebrikizumab for Moderate to Severe Atopic Dermatitis in Patients 12 Years and Older

June 25th 2024

Authorization for Eli Lilly's Ebglyss is based on positive results from the ADvocate 1, ADvocate 2, and ADhere studies.

Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation
Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation

June 21st 2024

Alexandra Golant, MD: Insights from Olympic Athlete Suni Lee's Journey with Atopic Dermatitis
Alexandra Golant, MD: Insights from Olympic Athlete Suni Lee's Journey with Atopic Dermatitis

June 18th 2024

Analyzing the Impact of AD on Women’s Sexual Health
Analyzing the Impact of AD on Women’s Sexual Health

June 13th 2024

FDA Approves Tralokinumab Autoinjector for Adults With Moderate to Severe Atopic Dermatitis
FDA Approves Tralokinumab Autoinjector for Adults With Moderate to Severe Atopic Dermatitis

June 13th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.